Galmed Pharmaceuticals's total assets for Q3 2024 were $20.95M, an increase of 57.03% from the previous quarter. GLMD total liabilities were $2.51M for the fiscal quarter, a 61.78% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.